Paula Rodríguez‐Otero
YOU?
Author Swipe
View article: Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs Open
Infections remain a key challenge during treatment of multiple myeloma (MM) patients with anti-BCMA and -GPRC5D bispecific antibodies (bsAbs). However, the underlying mechanism behind different rates and severity of infections induced by t…
View article: Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent
Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent Open
MonumenTAL‑1, ClinicalTrials.gov identifier NCT03399799/NCT04634552; LocoMMotion, ClinicalTrials.gov identifier NCT04035226; MoMMent, ClinicalTrials.gov identifier NCT05160584.
View article: Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3 Open
Introduction: In RRMM, increasing rates of pt attrition and decreasing durability of responses with each line of therapy (LOT) necessitate early treatment (tx) with the most effective therapies. Immunotherapies that are widely accessible a…
View article: The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data
The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data Open
Background: ARI0002h (cesnicabtagene autoleucel) is a BCMA-CART developed at Hospital Clinic de Barcelona (HCB). Approval was granted by the Spanish Medicines Agency (AEMPS) under the hospital exemption clause in August 2024, based on the …
View article: Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network Open
The treatment landscape of heavily pretreated relapsed/refractory MM has changed considerably in recent years with the introduction of novel BCMA‐ and GPRC5D‐directed immunotherapies, including CAR T‐cell therapy, bispecific antibodies (Bs…
View article: Emerging Risk of <i>Campylobacter</i> spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies
Emerging Risk of <i>Campylobacter</i> spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies Open
Bispecific antibodies directed against BCMA and GPRC5D have shown remarkable efficacy in patients with refractory multiple myeloma; however, concerns regarding infection risk are emerging. In a cohort of 85 treated patients, we observed a …
View article: Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h Open
Background Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized multiple myeloma treatment (MM). However, managing its immune-mediated adverse events, particularly macrophage activa…
View article: An open CAR-T single-cell atlas to enable in-depth characterization and rational engineering of CAR-T products
An open CAR-T single-cell atlas to enable in-depth characterization and rational engineering of CAR-T products Open
BRIEF ABSTRACT We built a CAR-T cell functional atlas from over one million cells across 13 studies, integrating data from patients and healthy donors. The atlas captures 11 phenotypes, links infusion product composition with clinical resp…
View article: Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone Open
Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab with bortezomib/lenalidomide/dexamethas…
View article: Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma
Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma Open
PURPOSE This analysis aimed to contextualize the symptoms of peripheral neuropathy (PN) experienced by patients with triple-class refractory (TCR) multiple myeloma (MM) treated with elranatamab in the MagnetisMM-3 clinical trial with those…
View article: B01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL)
B01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL) Open
Background. The phase III IsKia trial evaluated isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) as pre-ASCT induction and post-ASCT consolidation vs KRd in NDMM patients (pts). Here we report the rates of 1-year sustained (sust)…
View article: Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study Open
Talquetamab, a G protein–coupled receptor class C group 5 member D–targeting bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. …
View article: Supplementary Table 11 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 11 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Quantification of stool metabolites in multiple myeloma patients from the first cohort, measured by nuclear magnetic resonance (NMR) on the day of apheresis, lymphodepletion or 12 monts post CAR-T cell infusion. Apheresis Sample ID Acetate…
View article: Supplementary Table 5 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 5 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Linear regression analysis identifying independent predictors of CD4+ central memory level
View article: Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
upplementary Figure S10 provides a phenotypic characterization of in vitro expanded CAR T-cells that were supplemented with succinate. This includes an analysis of CD4+ naive and terminally differentiated effector T cells, as well as CD4+ …
View article: Supplementary Table 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Main characteristics of the patients, response and safety
View article: Supplementary Table 15 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 15 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Relative quantification of succinic acid in serum of MM patients from the first cohort at apheresis day, using the targeted UHPLC-MS methodology. UHPLC-MS: Ultra High-Performance Liquid Chromatography Mass Spectrometry
View article: Supplementary Table 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Relative quantification of inosine in serum of MM patients from the first cohort at different time points, using the targeted UHPLC-MS methodology. V1: Apheresis day, V11: 28 days post CAR-T infusion, 12M: 12 months post CAR-T infusion, UH…
View article: Supplementary Table 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Distribution of patients that donated at least one stool sample to the study in cohort 1 and were treated.
View article: Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Multiple myeloma remains incurable despite advances in immunotherapies like chimeric antigen receptor (CAR) T-cell therapy. This study investigates the role of metabolites and gut microbiota in clinical outcomes in patients treated with th…
View article: Supplementary Table 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
SCFA evaluation in serum of MM patients from the first cohort at the apheresis day, using gas chromatography-mass spectrometry methodology
View article: Supplementary Figure 24 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 24 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S24 shows the association between alpha diversity and clinical outcomes, specifically presenting Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS). These curves compare patients with hig…
View article: Supplementary Figure 23 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 23 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S23 shows a network of correlations between gut microbial families (green nodes) and metabolites (yellow nodes) associated with clinical response improvement. Green lines denote positive correlations, while red lines i…
View article: Supplementary Figure 4 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 4 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S4 illustrates the pre and post-CAR T-cell infusion systemic short-chain fatty acid profiles in multiple myeloma patients, specifically detailing levels of acetate, propionate, butyrate, isobutyrate, and formate.
View article: Supplementary Figure 18 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 18 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S18 presents LDA scores that indicate differences in taxonomic abundance based on toxicity profiles in multiple myeloma (MM) patients. The figure shows comparisons between patients with and without cytokine release syn…
View article: Supplementary Table 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Metabolite enrichment analysis using metabolites identified in the combined model. Statistical significance was assessed using the false discovery rate (FDR).
View article: Supplementary Table 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
The potential impact of antibiotic usage on gut microbiota 1st cohort.